Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.
These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.
CYP450 isoenzymes, particularly CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP1A2, exhibit significant genetic polymorphism. CYP2D6 is highly polymorphic and metabolizes nearly 25% of commonly prescribed drugs.
Genetic variants in these enzymes result in distinct metabolizer phenotypes: poor, intermediate, extensive (normal), and ultra-rapid metabolizers. These phenotypes profoundly influence drug plasma levels, therapeutic efficacy, and the risk of adverse effects.
The pharmacokinetic variability due to CYP polymorphisms has critical clinical implications. For instance, CYP2C9 poor metabolizers exhibit reduced clearance of warfarin, heightening the risk of bleeding complications.
Conversely, individuals with ultra-rapid CYP2C19 activity may show subtherapeutic levels of proton pump inhibitors like omeprazole, reducing treatment efficacy for acid-related disorders. CYP2D6 ultra-rapid metabolizers may convert codeine to morphine more rapidly, risking opioid toxicity.
Pharmacogenomic testing enables the identification of genetic variants in CYP genes. While cost, turnaround time, and accessibility may limit routine testing, it provides valuable guidance for dose adjustments or alternative therapies.
Regulatory bodies such as the FDA increasingly incorporate pharmacogenomic recommendations into drug labels, fostering safer, patient-specific prescribing practices and supporting the broader goals of precision medicine.
Cytochrome P450 isoenzymes carry out oxidative metabolism of xenobiotics, including drugs and endogenous compounds, during Phase I biotransformation.
These isoenzymes are grouped into families using numbers and subfamilies using letters based on amino acid sequence similarity.
Interestingly, some isoenzymes show high genetic variability with varying degrees of polymorphism. For example, CYP2D6 is the most polymorphic and metabolizes approximately 25% of clinically used drugs.
Genetic variations in CYP450 enzyme activity can classify individuals as poor, intermediate, normal, or ultra-rapid metabolizers—categories that affect drug efficacy and side effect profile.
For instance, when taking warfarin, poor metabolizers with CYP2C9 variants have a higher risk of bleeding. Ultra-rapid CYP2C19 metabolizers may experience rapid omeprazole clearance. So they may not get enough acid suppression.
Genetic testing revealing such variations has led the FDA to include pharmacogenomic details, such as safety warnings and dosage adjustments, in drug labels for personalized treatment.
繁體中文
